KCRS 2021 - 3rd Annual Kidney Cancer Research Summit
Oct 07 - Oct 08, 2021 | PhiladelphiaPAUS
LARVOL is not affiliated with 3rd Annual Kidney Cancer Research Summit and all trademarks, logos, and brand names are property of their respective owners
Showing 16 abstracts linked to Trials
Potential Role of Seleno-LMethionine (SLM) in Stabilization of Tumor Vasculature and Enhanced Efficacy of Axitinib in Previously Treated Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
A phase 3 trial of lenvatinib plus pembrolizumab versus sunitinib as a first-line treatment for patients with advanced renal cell carcinoma: overall survival follow-up analysis (the CLEAR study)
Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: a randomized phase Ib study and in-depth analysis of gut microbiome evolution
Pembrolizumab (pembro) vs placebo as post nephrectomy adjuvant therapy for patients with renal cell carcinoma (RCC): randomized, double-blind, phase 3 KEYNOTE-564 study
MK-1308A + lenvatinib and pembrolizumab + belzutifan + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for clear cell renal cell carcinoma: randomized, open-label, phase 3 study
Pembrolizumab with lenvatinib in the first-line setting for non–clear cell renal cell carcinoma: Openlabel, phase 2 KEYNOTE-B61 study
A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)
Characterization of responders in the phase 3 CheckMate 9ER trial: nivolumab plus cabozantinib versus sunitinib in patients with previousl untreated advanced renal cell carcinoma
Characterization of responders in the phase 3 CheckMate 9ER trial: nivolumab plus cabozantinib versus sunitinib in patients with previously untreated advanced renal cell carcinoma
Phase II trial of Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)
ORCHID: A phase II study of Olaparib in Metastatic Renal Cell Carcinoma Patients HarborIng a BAP1 or Other DNA Repair Gene Mutations
Randomized, open-label, phase 3 study of belzutifan plus lenvatinib versus cabozantinib in patients with advanced renal cell carcinoma after anti–PD-1/PD-L1 therapy
Treatment of advanced renal cell carcinoma after progression on systemic therapy: An open-label phase 2 study of 2 doses of the HIF-2α inhibitor belzutifan
A Phase 1b/2 randomized study of AVB-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment
[VIRTUAL] Combining Locally Administered Ipilimumab with a Personalized Neoantigen Cancer Vaccine to Improve T-Cell Priming and Antitumor Immunity in High-Risk Renal Cell Carcinoma